- ►diabetesjournals.org MS Fineman, TA Bicsak, LZ Shen, K Taylor, E … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—All three AC2993 regimens led to significant reductions in serum fructosamine relative to
placebo (P ≤ 0.004). Mean reductions ranged from 39 to 46 μmol/l. All AC2993 groups had
reductions in HbA 1c ranging from ... Cited by 231 - Related articles - BL Direct - All 10 versions
- ►endojournals.org OG Kolterman, JB Buse, MS Fineman, E Gaines … - Journal of Clinical …, 2003 - Endocrine Soc Despite the advent of new treatments, glucose control in the type 2 diabetes population is
unsatisfactory. AC2993 (synthetic exendin-4; exenatide), a novel glucose-dependent insulinotropic
agent, exhibited notable ... Cited by 277 - Related articles - BL Direct - All 6 versions
MS Fineman, LZ Shen, K Taylor, DD Kim, … - Diabetes/Metabolism … - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets. In
this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the ... Cited by 113 - Related articles - BL Direct - All 3 versions
- ►diabetesjournals.org JB Buse, RR Henry, J Han, DD Kim, MS Fineman, … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—At week 30, HbA 1c changes from baseline were −0.86 ± 0.11, −0.46 ± 0.12, and 0.12
± 0.09% (±SE) in the 10-μg, 5-μg, and placebo arms, respectively (adjusted P < 0.001). Of
evaluable subjects with baseline ... Cited by 455 - Related articles - BL Direct - All 13 versions
LL Nielsen, AA Young, DG Parkes - Regulatory peptides, 2004 - Elsevier Exenatide (synthetic exendin-4), glucagon-like peptide-1 (GLP-1), and GLP-1 analogues have actions
with the potential to significantly improve glycemic control in patients with diabetes. Evidence
suggests that these agents use a ... Cited by 185 - Related articles - All 7 versions
RA DeFronzo, RE Ratner, J Han, DD Kim, MS … - Diabetes care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A triple-blind, placebo-controlled, 30-week study at 82 US sites was
performed with 336 randomized patients. In all, 272 patients completed the study. The
intent-to-treat population baseline ... Cited by 644 - Related articles - All 6 versions
- ►physiology.org CMB Edwards, SA Stanley, R Davis, AE … - American Journal of …, 2001 - Am Physiological Soc Exendin-4 is a long-acting potent agonist of the glucagon-like peptide 1 (GLP-1) receptor and may be
useful in the treatment of type 2 diabetes and obesity. We examined the effects of an intravenous
infusion of exendin-4 (0.05 pmol · ... Cited by 234 - Related articles - BL Direct - All 4 versions
CB Juhl, M Hollingdal, J Sturis, G Jakobsen, H Agersø, … - Diabetes, 2002 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) is a potent glucose-lowering agent of potential interest for the
treatment of type 2 diabetes. To evaluate actions of NN2211, a long-acting GLP-1 derivative, we
examined 11 patients with type 2 ... Cited by 175 - Related articles - BL Direct - All 6 versions
DM Kendall, MC Riddle, J Rosenstock, D Zhuang, … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Week 30 A1C changes from baseline (±SE) were −0.8 ± 0.1% (10 μg), −0.6 ± 0.1% (5
μg), and +0.2 ± 0.1% (placebo; adjusted P < 0.0001 vs. placebo), yielding placebo-adjusted
reductions of −1.0% (10 μg) and ... Cited by 548 - Related articles - All 11 versions
OG Kolterman, DD Kim, L Shen, JA Ruggles, LL … - American Journal of …, 2005 - ASHP R UGGLES , P H .D., is Associate Director Medical Writing, Medical Af- fairs; L ORETTA L. N IELSEN ,
P H .D., is Senior Medical Writer, Medical Affairs; M ARK S. F INEMAN , BS, is Senior Director,
Clinical Affairs; and A LAIN D. B ... Cited by 141 - Related articles - All 5 versions
